Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Doug, Grove"'
Autor:
Rujeko Mashingaidze, Zoe Moodie, Mary Allen, Linda-Gail Bekker, Doug Grove, Nicole Grunenberg, Yunda Huang, Holly E Janes, Erica Maxine Lazarus, Mookho Malahleha, Maphoshane Nchabeleng, Fatima Laher
Publikováno v:
PLOS Global Public Health, Vol 3, Iss 4, p e0001782 (2023)
There is limited data about bacterial STIs in MSM populations in sub-Saharan Africa. Our retrospective analysis used data from the HVTN 702 HIV vaccine clinical trial (October 2016 to July 2021). We evaluated multiple variables. Polymerase chain reac
Externí odkaz:
https://doaj.org/article/8c2323d8afd840b6b67a1f0bd8ab42d7
Autor:
Zoe Moodie, One Dintwe, Sheetal Sawant, Doug Grove, Yunda Huang, Holly Janes, Jack Heptinstall, Faatima Laher Omar, Kristen Cohen, Stephen C De Rosa, Lu Zhang, Nicole L Yates, Marcella Sarzotti-Kelsoe, Kelly E Seaton, Fatima Laher, Linda Gail Bekker, Mookho Malahleha, Craig Innes, Sheetal Kassim, Nivashnee Naicker, Vaneshree Govender, Modulakgotla Sebe, Nishanta Singh, Philip Kotze, Erica Lazarus, Maphoshane Nchabeleng, Amy M Ward, William Brumskine, Thozama Dubula, April K Randhawa, Nicole Grunenberg, John Hural, Jia Jin Kee, David Benkeser, Yutong Jin, Lindsay N Carpp, Mary Allen, Patricia D’Souza, James Tartaglia, Carlos A DiazGranados, Marguerite Koutsoukos, Peter B Gilbert, James G Kublin, Lawrence Corey, Erica Andersen-Nissen, Glenda E Gray, Georgia D Tomaras, M Juliana McElrath
Publikováno v:
J Infect Dis
Background The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates of HIV-1 acquisiti
Autor:
Abby Isaacs, Janan Dietrich, Joan Dragavon, Maria P. Lemos, John Hural, Reena K Gulati, M J McElrath, Erica Lazarus, Michele P. Andrasik, Doug Grove, Eva Chung, Robert W. Coombs, Glenda Gray, Adrian Puren, Cecilia Morgan, Fatima Laher, James G. Kublin, Yunda Huang
Publikováno v:
J Acquir Immune Defic Syndr
Background Measurements of HIV exposure could help identify subpopulations at highest risk of acquisition and improve the design of HIV prevention efficacy trials and public health interventions. The HVTN 915 study evaluated the feasibility of self-a
Autor:
Philip Kotze, Fatima Laher, Mary Allen, Peter B. Gilbert, Jia J. Kee, Dishiki Jenny Kalonji, Carter Bentley, Susan W. Barnett, Tricia Philip, Craig Innes, Adrian Puren, Holly Janes, Millicent Atujuna, Nivashnee Naicker, M. Juliana McElrath, Philisiwe B. Makhoba, Gladys Kobane, Girisha Kistnasami, Katlego S. Mapetla, Zakir Gaffoor, Cleon N. Ncayiya, Sanjay Phogat, Vimla Naicker, Simbarashe Takuva, James G. Kublin, Linda-Gail Bekker, Nima S. Hejazi, David Benkeser, Niranjan Kanesa-thasan, Modulakgotla Sebe, Olivier Van Der Meeren, Yunda Huang, Bontle Modibedi, Pamela Mda, Mookho Malahleha, Mpho Sikhosana, Matsontso Mathebula, Pearl Selepe, Amy Ward, Lawrence Corey, Megan Jones, John Hural, Tania Adonis, Sheetal Kassim, Carlos Diaz Granados, Nicole Grunenberg, Shelly Ramirez, Doug Grove, Maphoshane Nchabeleng, Brittany Prigmore, Graeme Meintjes, Erica Lazarus, William Brumskine, Lubbe Wiesner, Nigel Garrett, Marguerite Koutsoukos, Thozama Dubula, Zoe Moodie, Glenda Gray, Nishanta Singh, Michele P. Andrasik
Publikováno v:
The New England journal of medicine. 384(12)
Background A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. An analogous
Autor:
Gavin J Churchyard, Cecilia Morgan, Elizabeth Adams, John Hural, Barney S Graham, Zoe Moodie, Doug Grove, Glenda Gray, Linda-Gail Bekker, M Juliana McElrath, Georgia D Tomaras, Paul Goepfert, Spyros Kalams, Lindsey R Baden, Michelle Lally, Raphael Dolin, William Blattner, Artur Kalichman, J Peter Figueroa, Jean Pape, Mauro Schechter, Olivier Defawe, Stephen C De Rosa, David C Montefiori, Gary J Nabel, Lawrence Corey, Michael C Keefer, NIAID HIV Vaccine Trials Network
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e21225 (2011)
The safety and immunogenicity of a vaccine regimen consisting of a 6-plasmid HIV-1 DNA prime (envA, envB, envC, gagB, polB, nefB) boosted by a recombinant adenovirus serotype-5 (rAd5) HIV-1 with matching inserts was evaluated in HIV-seronegative part
Externí odkaz:
https://doaj.org/article/5dc1c0316ec6406fbd78dd8ab1a777f9
Publikováno v:
Vaccine
BACKGROUND HIV disproportionately impacts transgender populations globally, creating challenges to inclusion in trials requiring low HIV risk profiles (LHRP) for acquisition. Our knowledge of transgender individuals with LHRP is limited. We conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e846e7a908c2fbd4c89d8bb9a948d99
https://europepmc.org/articles/PMC6699617/
https://europepmc.org/articles/PMC6699617/
Autor:
Jonathan D, Fuchs, Magdalena E, Sobieszczyk, Tamra, Madenwald, Doug, Grove, Shelly T, Karuna, Michele, Andrasik, Adam, Sherwat, Gail, Broder, Kenneth, Mayer, Beryl, Koblin, Scott, Hammer, Coco, Alinsug
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 63:259-262
In November 2010, the iPrEx study reported that pre-exposure prophylaxis (PrEP) with daily tenofovir disoproxil fumarate/emtricitabine reduced HIV infections by 44% among men who have sex with men and subsequent trials corroborated efficacy among het
Autor:
Kaitlin Sawatzki, Robert Parks, Ruijun Zhang, Axin Hua, M. Anthony Moody, Dawn J. Marshall, Richard A. Koup, Hua-Xin Liao, Wilton B. Williams, Andrew Foulger, S. Munir Alam, Jae-Sung Yu, Hongshuo Song, Kathryn J. Jones, Cecilia Morgan, Peter B. Gilbert, Lindsey R. Baden, Kevin Wiehe, Lawrence Corey, Gavin J. Churchyard, John F. Whitesides, Georgia D. Tomaras, Krissey E. Lloyd, Nathan Vandergrift, Xiaoying Shen, Gary J. Nabel, Scott M. Hammer, David C. Montefiori, Thomas B. Kepler, Janine Maenza, Michael C. Keefer, Ashley M. Trama, Shelly Karuna, M. Juliana McElrath, Pinghuang Liu, Guido Ferrari, Magdalena E. Sobieszczyk, John R. Mascola, Barney S. Graham, Nicole Grunenberg, Doug Grove, Feng Gao, Barton F. Haynes, Matthew Zirui Tay, Justin Pollara, Kelly E. Seaton
Publikováno v:
Science. 349
Microbiota can mislead antibodies Unlike the response to many viral infections, most people do not produce antibodies capable of clearing HIV-1. Non-neutralizing antibodies that target HIV-1's envelope glycoprotein (Env) typically dominate the respon
Autor:
Wilton B, Williams, Hua-Xin, Liao, M Anthony, Moody, Thomas B, Kepler, S Munir, Alam, Feng, Gao, Kevin, Wiehe, Ashley M, Trama, Kathryn, Jones, Ruijun, Zhang, Hongshuo, Song, Dawn J, Marshall, John F, Whitesides, Kaitlin, Sawatzki, Axin, Hua, Pinghuang, Liu, Matthew Z, Tay, Kelly E, Seaton, Xiaoying, Shen, Andrew, Foulger, Krissey E, Lloyd, Robert, Parks, Justin, Pollara, Guido, Ferrari, Jae-Sung, Yu, Nathan, Vandergrift, David C, Montefiori, Magdalena E, Sobieszczyk, Scott, Hammer, Shelly, Karuna, Peter, Gilbert, Doug, Grove, Nicole, Grunenberg, M Juliana, McElrath, John R, Mascola, Richard A, Koup, Lawrence, Corey, Gary J, Nabel, Cecilia, Morgan, Gavin, Churchyard, Janine, Maenza, Michael, Keefer, Barney S, Graham, Lindsey R, Baden, Georgia D, Tomaras, Barton F, Haynes
Publikováno v:
Science (New York, N.Y.). 349(6249)
An HIV-1 DNA prime vaccine, with a recombinant adenovirus type 5 (rAd5) boost, failed to protect from HIV-1 acquisition. We studied the nature of the vaccine-induced antibody (Ab) response to HIV-1 envelope (Env). HIV-1-reactive plasma Ab titers were
Autor:
Scott M, Hammer, Magdalena E, Sobieszczyk, Holly, Janes, Shelly T, Karuna, Mark J, Mulligan, Doug, Grove, Beryl A, Koblin, Susan P, Buchbinder, Michael C, Keefer, Georgia D, Tomaras, Nicole, Frahm, John, Hural, Chuka, Anude, Barney S, Graham, Mary E, Enama, Elizabeth, Adams, Edwin, DeJesus, Richard M, Novak, Ian, Frank, Carter, Bentley, Shelly, Ramirez, Rong, Fu, Richard A, Koup, John R, Mascola, Gary J, Nabel, David C, Montefiori, James, Kublin, M Juliana, McElrath, Lawrence, Corey, Peter B, Gilbert, Michael T, Yin
Publikováno v:
The New England journal of medicine. 369(22)
A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime-recombinant adenovirus type 5 boost (DNA/rAd5) vaccine regimen in persons at increase